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Summary
 
Recent studies have shown that the brain is not a barrier to successful active immunotherapy
that uses gene-modified autologous tumor cell vaccines. In this study, we compared the effi-
cacy of two types of vaccines for the treatment of tumors within the central nervous system
(CNS): dendritic cell (DC)-based vaccines pulsed with either tumor extract or tumor RNA,
and cytokine gene–modified tumor vaccines. Using the B16/F10 murine melanoma (B16) as a
model for CNS tumor, we show that vaccination with bone marrow–generated DCs, pulsed
with either B16 cell extract or B16 total RNA, can induce specific cytotoxic T lymphocytes
against B16 tumor cells. Both types of DC vaccines were able to protect animals from tumors
located in the CNS. DC-based vaccines also led to prolonged survival in mice with tumors
placed before the initiation of vaccine therapy. The DC-based vaccines were at least as effec-
tive, if not more so, as vaccines containing B16 tumor cells in which the granulocytic mac-
rophage colony-stimulating factor gene had been modified. These data support the use of DC-
based vaccines for the treatment of patients with CNS tumors.
 
T
 
he concept that the brain is an immunologically privi-
leged site has been supported clinically by the failure
of central nervous system (CNS) tumors to respond to im-
munotherapy protocols that were successful systemically (1,
2). Recently, several groups including ours have described
active immunotherapy protocols using intradermal vaccines
of genetically modified tumor cells as being effective in ro-
dent brain tumor models (3, 4). However, animal studies
have shown that immunization with CNS-derived tumor
material can induce fatal experimental allergic encephalitis
(5). Due to the limited ability of reliably obtaining and
growing a high percentage of tumor specimens without
contamination by normal nervous tissue, the application of
similar approaches to human patients with brain tumors
may therefore carry the risk of causing such autoimmune
complications (6, 7).
The dendritic cell (DC) network is a specialized system
for presenting antigen to naive or quiescent T cells, and it
plays a central role in the induction of T and B cell immu-
nity in vivo. Immunizations using DCs loaded with tumor
antigens may, therefore, represent a powerful method of
inducing antitumor immunity. Recent studies have shown
that immunizing mice with DCs pulsed with specific anti-
gens can prime a CTL response that is tumor-specific and
engenders protective tumor immunity in the treated mice
(8–10). Immunization using defined tumor antigens is, how-
ever, limited at present to a handful of human tumor types
in which candidates for tumor rejection antigens have been
identified (11). More recently, effective tumor immunity in
mice was induced using DCs pulsed with unfractionated
tumor-derived antigens in the form of peptides (12, 13),
cell sonicates (14), or messenger RNA (mRNA; 15). The
advantages of vaccinating with total tumor-derived material
are that the identity of the tumor antigen(s) need not be
known and that the presence of multiple tumor antigens
reduces the risk of antigen-negative escape mutants. The
potential benefit of using total tumor antigens in the form
of mRNA is that it can be amplified from a small number
of tumor cells. Hence, DC vaccine treatment may be ex-
tended to patients with brain tumors from which only a
small, possibly microscopic, biopsy can be taken for diag-
nosis. Furthermore, isolating bona fide tumor cells from
patient specimens by ex vivo purification methods and
combing this with the use of RNA subtractive hybridiza-
tion techniques may reduce the concentration of self, po-
tentially autoreactive, antigens in the vaccine preparation.
This would be of crucial importance for vaccinations with
CNS tumor-derived antigens, as it may diminish the risk of
severe autoimmune complications.
The studies presented here evaluated and compared the
efficacy of DC-based tumor vaccines pulsed with either tu-
mor extract or tumor-derived total RNA, with that of tu-
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mor vaccines in which the gene for GM-CSF had been
modified. The vaccines were studied in a model of active
immunotherapy for CNS tumors.
 
Materials and Methods
 
Tumor Cell Lines and Animal Models.
 
The B16/F10 murine
melanoma cell line (B16) derived from a spontaneous melanoma
in a C57BL/6 mouse (H-2
 
b
 
) was provided by I. Fidler (M.D.
Anderson Cancer Center, Houston, TX; reference 16). The
SMA 560 cell line was derived from an intracerebral transplant of
a spontaneous astrocytoma from a VM/Dk mouse (H-2
 
b
 
) (17).
The SMA 560 cell line was chosen as a control for the B16, since
both cell lines are derived from neural crest. EL-4 (H-2
 
b
 
) murine
thymoma cells were obtained from American Type Tissue Cul-
ture Collection (Rockville, MD). Cell lines were grown in zinc
option medium (GIBCO BRL, Gaithersburg, MD) containing
5% (vol/vol) FCS. All cell lines were shown to be free from 
 
My-
coplasma
 
 contamination as previously described (18). All experi-
ments used 6–12-wk-old female C57BL/6 mice (The Jackson
Laboratory, Bar Harbor, ME), which were maintained in a virus-
free environment in accordance with the Laboratory Animal Re-
sources Commission standards.
 
DC Generation from Bone Marrow Cultures.
 
The procedure used
in these studies was the same as previously described (8, 19). In
brief, bone marrow was flushed from the long bones of the limbs
and depleted of red cells with ammonium chloride. Bone marrow
cells were depleted of lymphocytes, granulocytes, and Ia
 
1
 
 cells
using a mixture of mAbs and complement. The mAbs used were
2.43 or 53-6.72 (CD8), GK1.5 (CD4), RA3-3A1/6.1 (CD45R),
B21-2 anti-Ia (Tumor Immunology Bank 210, 105, 207, 146, and
229, respectively; American Type Tissue Culture Collection),
and RB6-8C5 anti–Gr-1 (provided by DNAX, Palo Alto, CA).
Cells were plated in 6-well culture plates (10
 
6
 
 cells/ml, 3 ml/
well) in RPMI 1640 medium supplemented with 5% heat-inacti-
vated FCS, 50 mM 2-mercaptoethanol, 10 mM Hepes (pH 7.4),
2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 3.3 ng/ml GM-CSF (provided by Amgen, Inc., Thousand
Oaks, CA). On day 3 of culture, floating cells were gently re-
moved, and fresh medium was added. On day 7 of culture, non-
adherent cells and loosely adherent proliferating DC aggregates
were collected and replated in 100-mm Petri dishes (10
 
6
 
 cells/ml,
10 ml/dish). At 10 d of culture, nonadherent cells (DCs) were re-
moved for analysis and immunizations.
The quality of DC preparation was characterized by cell sur-
face marker analysis, morphological analysis, and the ability of the
preparation to induce OVA-specific CTLs in immunized mice as
previously described (data not shown; references 19, 20).
 
Vaccination with DCs Pulsed with Tumor Extracts.
 
DCs were
washed  twice in Opti-MEM medium (GIBCO BRL) and then
resuspended at 5–10 
 
3
 
 10
 
6
 
 cells/ml in 50 ml polypropylene tubes
(Falcon, Lincoln Park, NJ). The cationic lipid, DOTAP, (Boeh-
ringer Mannheim Biochemicals, Indianapolis, IN) was used to
deliver tumor extracts into cells. Tumor extracts were obtained
by sonicating tumor cells in Opti-MEM (10
 
7
 
 cells/500 
 
m
 
l) using a
Special Ultrasonic Cleaner (Laboratory Supplies Company,
Hicksville, NY) and were used without any further manipulation.
Tumor extracts (500 
 
m
 
l) and DOTAP (125 
 
m
 
g in 500 
 
m
 
l Opti-
MEM medium) were mixed in 12 
 
3
 
 75–mm polystyrene tubes at
room temperature for 20 min. The complex was added to the
DCs and incubated at 37
 
8
 
C in a water bath with occasional agita-
tion for 25 min. The cells were washed and resuspended in PBS
(10
 
5
 
 extract-pulsed DCs in 500 
 
m
 
l PBS/mouse) for intraperito-
neal immunizations.
 
Vaccination Using RNA-pulsed DCs.
 
Total RNA was isolated
from actively growing tissue culture cells by standard methods as
previously described (15). Pulsing DCs with RNA was per-
formed in serum-free Opti-MEM medium (GIBCO BRL) as de-
scribed for tumor extracts with the following modifications.
RNA (25 
 
m
 
g in 250 
 
m
 
l Opti-MEM medium) and DOTAP (50
 
m
 
g in 250 
 
m
 
l Opti-MEM medium) were mixed in 12 
 
3
 
 75 mm
polystyrene tubes at room temperature for 20 min. The complex
was added to the DCs (2–5 
 
3
 
 10
 
6
 
 cells/ml) and incubated at
37
 
8
 
C in a water bath with occasional agitation for 25 min. The
cells were washed twice and resuspended in PBS (10
 
5
 
 RNA-
pulsed DCs in 500 
 
m
 
l PBS/mouse) for intraperitoneal immuniza-
tions.
PBS, B16 extract from 10
 
5
 
 cells in PBS, or DCs prepared as
described above were injected intraperitoneally in a volume of
500 
 
m
 
l.
 
Vaccination with GM-CSF–secreting Tumor Cells.
 
Crip cells ge-
netically engineered to produce replication-incompetent recom-
binant retrovirus with an amphotropic host range and with the
ability to encode the cDNA for the murine GM-CSF gene were
used as previously described (4, 21). B16 cells were infected by
exposure to viral supernatants from these cells in the presence of
polybrene (Sigma Chemical Co., St. Louis, MO). GM-CSF pro-
duction from B16 cells exposed to virus was confirmed by ELISA
(Endogen, Cambridge, MA) and standard bioassays (21).
B16 parent cells with the modified GM-CSF gene and the un-
transfected cells were harvested, washed once in serum-contain-
ing medium, and washed twice in PBS. Cell pellets were resus-
pended in PBS at 10
 
5
 
/500 
 
m
 
l, irradiated (3,500 centiGray), and
injected subcutaneously. The subcutaneous route of administra-
tion was chosen because we previously demonstrated that this is
the preferred method for administering tumor vaccines (data not
shown).
 
In Vitro Cytotoxicity Assay.
 
In vitro cell–mediated cytotoxic-
ity assays were performed using standard procedures as we previ-
ously described (22). In this study, splenocytes obtained from im-
munized animals and controls were restimulated in vitro for 5 d
on monolayers of irradiated and mitomycin C–treated B16 cells
or SMA 560 cells. Target cells included SMA 560 and B16 cells.
 
Implantation of Brain Tumors.
 
B16 cells were harvested by
trypsinization, washed twice in Dulbecco’s PBS, and mixed with
an equal volume of 10% methylcellulose in zinc option medium.
The cells (500 cells in a volume of 5 
 
m
 
l) were then implanted into
the right caudate nucleus of the brain of C57BL/6 mice by ste-
reotactic injection as previously described (3, 4).
 
Statistical Analysis.
 
Survival estimates and median survivals
were determined using the method of Kaplan and Meier (23).
Survival data was compared using Wilcoxon’s log-rank test. Stu-
dent’s 
 
t
 
 test was used for calculating the significance of other data.
Statistical significance was determined at the 
 
,
 
0.05 level.
 
Results
 
Vaccination with Bone Marrow-derived DCs Pulsed with Tu-
mor Extract or Tumor RNA Induces Tumor-specific CTLs.
 
To test whether bone marrow–derived DCs pulsed with
tumor extracts or tumor RNA are capable of inducing tu-
mor-specific CTLs, we first immunized C57BL/6 mice
with three intraperitoneal injections of DCs spaced 1 wk
apart. Standard cytotoxicity assays were performed using 
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splenocytes harvested from immunized animals 7 d after the
third immunization and restimulated for 5 d in vitro with
irradiated B16 cells. Cytotoxic activity was tested against
B16 cells. We previously demonstrated that the B16 is a
poorly immunogenic tumor cell line such that no induc-
tion of CTLs occurs after immunization with unmodified
parent cells, and such immunization affords no antitumor
immunity in vivo (4).
As shown in Fig. 1, immunization using DCs pulsed
with either B16 tumor extract or B16 RNA induced B16-
specific CTL responses that were statistically significant
compared with animals immunized using DCs pulsed with
either SMA 560 tumor extract or SMA 560 RNA, or with
animals injected using PBS (Fig. 1, 
 
A
 
 and 
 
C
 
). Conversely,
splenocytes harvested from groups of animals immunized
with SMA 560–pulsed (extract or RNA) DCs specifically
lysed SMA 560 targets (Fig. 1, 
 
B
 
 and 
 
D
 
), further demon-
strating the tumor-specific nature of these responses. As
seen in Fig. 1, high levels of nonspecific lysis are observed
when animals are injected with bone marrow–derived DCs
pulsed with control antigen, but not those injected with
PBS. High levels of nonspecific lysis associated with the use
of bone marrow–derived DCs have been previously de-
scribed and were shown to be dependent upon the pres-
ence of sygeneic MHC class II molecules on the immuniz-
ing DCs (8) and can be partially overcome by the adherence
depletion of antigen-presenting cells before the restimula-
tion of effectors (19).
 
B16 Tumor Challenge in CNS After Immunization Using
DCs Pulsed with Tumor Extracts or RNA.
 
Next, experiments
were performed to determine whether vaccination using
B16-pulsed DCs generated specific and protective immu-
nity against B16 tumors within the CNS. Groups of
C57BL/6 mice received three intraperitoneal vaccinations
spaced 1 wk apart and composed of PBS, B16 extract alone,
or DCs pulsed with either B16– or SMA 560–derived ex-
tracts or RNA. Mice were then challenged in the brain 1
wk later with 500 viable B16 cells.
As shown in Fig. 2, immunizations with PBS, B16 ex-
tract alone, or DCs pulsed with SMA 560 extract or RNA
did not protect against CNS challenge with B16 cells. All
animals in these groups succumbed to tumor; median sur-
vival was between 21 and 24 d (Fig. 2, 
 
A
 
 and 
 
B
 
). In con-
trast, the median survival of animals undergoing vaccina-
tions of DCs pulsed with B16 extract was significantly
prolonged to 
 
.
 
80 d (
 
P
 
 
 
5
 
 0.0006), with 8 of 13 animals
surviving when the experiment was stopped at 80 d (Fig. 2
Figure 1. Induction of specific lytic activity against tumor cells by im-
munization with DC pulsed with tumor extracts or with tumor-derived
total RNA. Triplicate C57BL/6 mice were immunized three times with
either DC pulsed with (open circles) B16 tumor extract or (filled squares)
SMA 560 tumor extract (A and B, respectively), or with DC pulsed with
(open circles) B16 tumor RNA or (filled squares) SMA 560 RNA (C and D,
respectively) or with PBS (filled triangle). 7 d later, splenocytes were iso-
lated and restimulated for 5 d with irradiated B16 cells (A and C) or SMA
560 cells (B and D). Cytotoxic activity was then measured by chromium
release assay using the targets indicated in each panel. *(P ,0.05) indicate
points of significant differences in lysis when B16-immunized animals are
compared to SMA 560–immunized animals. Error bars indicate 1 SD of
the mean.
Figure 2. Vaccination with DCs pulsed with tumor extract or tumor
RNA protects against CNS challenge with B16 tumor and is equipotent
to vaccination with GM-CSF–producing B16 cells. Vaccination of
C57BL/6 mice was performed a total of three times before intracranial
tumor challenge with B16 cells as described in Materials and Methods.
Mice were evaluated daily until death. Data are representative of two ex-
periments performed with similar results. The results are divided in two
panels for clarity. The results for the PBS-immunized group (closed squares)
and the GM-CSF modified B16 cell immunized group (open squares) are
represented in both A and B for ease of comparison. Median days of sur-
vival, range, number of animals, and significance compared to PBS-
immunized animals based on log-rank analysis for each group are as fol-
lows: closed squares, PBS: 21, 13–41, n 5 10; X, DC pulsed with B16 tu-
mor extract: .80, 17–.80, n 5 13, P 5 0.0006; closed diamonds, DCs
pulsed with SMA 560 extract; 24, 19–30, n 5 11, P 5 0.50; closed trian-
gles, B16 extract: 21, 14–21, n 5 5, P 5 0.45; open squares, GM-CSF–
modified B16 cells: 36, 30–.80, n 5 6, P 5 0.022; open triangles, DC
pulsed with B16 RNA: 31, 19–.80, n 5 10, P 5 0.0001; open diamonds,
DC pulsed with SMA 560 RNA: 21, 15–31, n 5 9, P 5 0.40; open circles,
unmodified B16 cells: 23, 18–45, n 5 5, P 5 0.39.1180 Dendritic Cell Vaccines for Brain Tumors
A). Likewise, animals receiving vaccinations of DCs pulsed
with B16 RNA experienced a significant improvement in
median survival to 31 d (P 5 0.0001), with 4 of 10 animals
surviving when the experiment was stopped at 80 d. No
statistical significance was demonstrated in the difference
between groups immunized using DCs pulsed with either
B16 extract or RNA (P 5 0.29).
It has been convincingly demonstrated that vaccination
with tumor cells genetically engineered to secrete various cy-
tokines stimulates a potent immune response against tumors
outside the CNS (21, 24, 25). We recently showed that
subcutaneous vaccination with B16 cells that are genetically
engineered to produce GM-CSF stimulates a potent antitu-
mor immune response against B16 tumors located in the
brain and increases the survival of tumor-bearing C57BL/6
mice. It was, therefore, of interest to compare the efficacy
of DC-based immunotherapy with immunization using tu-
mor cells having the modified GM-CSF gene. As shown in
Fig. 2, A and B, mice vaccinated with GM-CSF gene-
modified B16 cells had a median survival of 36 d with two
of six mice surviving beyond 80 d, whereas mice vacci-
nated with B16 cells alone did not exhibit a survival advan-
tage. Vaccination using DCs pulsed with cell extracts (Fig.
2 A) or tumor RNA (Fig. 2 B) was as at least as effective as
vaccination using the B16 cells containing modified GM-
CSF. Although the median survival of the group vacci-
nated using DCs pulsed with B16 tumor extract was higher
than the group vaccinated with GM-CSF–modified B16
cells, the level of protection achieved with the DC-based
vaccines was not statistically greater than that obtained with
vaccines using GM-CSF–modified B16 cells (P 5 0.069).
Prolonged Survival of Mice Bearing CNS B16 Tumors and
Treated Using DCs Pulsed with B16 Tumor Extract. In con-
sidering the clinical application of a tumor vaccination
strategy, it is more realistic to treat animals with tumor
present at the time of vaccination. Thus, in the next exper-
iment, 500 B16 cells were implanted in the brain of naive
mice, and these mice were treated starting 4 d later, at
which point vascularized tumor can be demonstrated histo-
logically (4). Animals received treatments with three intra-
peritoneal vaccinations spaced 1 wk apart with PBS, DCs
pulsed with SMA 560 extract, or DCs pulsed with B16 ex-
tract (Fig. 3). Mice in the first two groups had median sur-
vivals of 16 d. Mice treated with the DCs pulsed with B16
extract had a significantly longer median survival of 26 d
(P 5 0.037), with two of seven animals surviving at 80 d
when the experiment was stopped.
Histologic Characterization of CNS Tumors in Immunized
Animals. CNS tumors from triplicate animals immunized
only once with PBS or DCs pulsed with B16 or control
EL-4 tumor extract were examined histologically. Tumors
of the group vaccinated with DCs pulsed with B16 extract
demonstrated large areas of hemorrhage and necrosis with
an associated heavy inflammatory infiltrate composed of
both mononuclear cells and polymorphonuclear leukocytes.
In comparison, no such areas were observed in either con-
trol group (Fig. 4). Outside the immediate peritumoral re-
gions, the brain parenchyma appeared histologically normal.
Discussion
In this study, we showed that immunization with DCs
pulsed with either unfractionated tumor extracts or with
Figure 3. Treatment of estab-
lished CNS B16 tumors with
DCs pulsed with tumor extract
prolongs survival. Intracranial tu-
mor challenge with B16 cells was
performed first and then, start-
ing 4 d later, C57BL/6 mice
were treated with a total of three
immunizations as described in
Materials and Methods. Mice
were evaluated daily until death.
Median days of survival, range,
number of animals, and significance compared to PBS-immunized ani-
mals based on log-rank analysis for each group are as follows: filled squares,
PBS: 16, 15–18, n 5 6; X, DC pulsed with B16 tumor extract: 26, 14–
.80, n 5 7, P 5 0.037; (filled diamonds), DC pulsed with SMA 560 ex-
tract: 16, 15–26, n 5 7, P 5 0.57.
Figure 4. CNS B16 tumors from animals vaccinated with DC pulsed
with B16 tumor extract demonstrate large areas of necrosis, hemorrhage,
and inflammatory infiltrate (b). No such changes are seen in CNS B16 tu-
mors from animals vaccinated with DC pulsed with control tumor extract
(a) or PBS (not shown).1181 Ashley et al.  Brief Definitive Report
total tumor RNA elicits potent immunity against CNS tu-
mors in mice. We showed that this therapy can be used for
both protection against CNS tumor challenge and in the
treatment of established tumors. Furthermore, when com-
pared directly, B16-pulsed DCs had potency at least equiv-
alent to GM-CSF–modified B16 vaccines.
A number of barriers exist, in practice, to the treatment
of human brain tumors using genetically modified autolo-
gous tumor cell vaccines. These vaccines require the con-
siderable tasks of ex vivo purification, culture, expansion,
and transfection of tumor specimens, a difficult undertaking
even for tumors outside the CNS (6, 7). DC-based vac-
cines may overcome some of these problems. First, human
DCs can be generated from peripheral blood; therefore,
supplies are not limited. Secondly, the ex vivo manipula-
tions required to produce antigen-pulsed DCs are simpler
than those required for generating autologous tumor cell
vaccines.
It has been shown that immunizing nonhuman primates
and guinea pigs with human glioblastoma multiforme tissue
can induce allergic encephalomyelitis that is lethal (5). Vac-
cination with unfractionated tumor–derived antigens, such
as those possibly contained in an autologous tumor cell
vaccine derived from the CNS and modified genetically,
may lead to potentially disastrous consequences such as au-
toimmune encephalitis. This risk may limit the use of such
vaccines to a minority of patients: those suffering with
brain tumors from which highly purified tumor specimens
can not be guaranteed. One approach that may overcome
these drawbacks is to use, as a source of antigen, mRNA
from tumor cells. In the case of brain tumors, an important
advantage is that RNA may allow the use of subtractive
hybridization techniques to reduce the concentration of
antigens shared between tumor and normal CNS tissue, less-
ening the potential for autoimmunity.
By demonstrating that vaccines based on DCs pulsed
with tumor extracts or RNA are active against CNS tumors
and are equipotent to cytokine gene–modified vaccines, these
studies establish a basis for future preclinical studies of hu-
man DC-based vaccines for treating brain tumors.
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